Introduction {#s1}
============

Lung cancer is now the most commonly diagnosed cancer and the leading cause of cancer mortality in both men and women worldwide. Since less females smoke than males or females started smoking later than males, lung cancer trends among females lag behind males [@pone.0071236-Siegel1]. However, lung cancer incidence still keeps increasing [@pone.0071236-Siegel2]. Besides smoking, several occupational and environmental carcinogens such as asbestos, arsenic and radon are known to be risk factors for lung cancer in females [@pone.0071236-Siegel1]. Hormone replacement therapy (HRT) remains the most effective treatment for postmenopausal symptoms in menopausal females and young females who go into early menopause due to surgery or chemotherapy or radiotherapy to the pelvic region [@pone.0071236-Biglia1]. Adami et al. first demonstrated that lung cancer risk increased in women receiving HRT [@pone.0071236-Adami1]. During the past two decades, studies on the HRT and lung cancer risk have demonstrated contradictory results, making the association still remained uncertain. Two clinical trials from Chlebowski confirmed the correlation between increased lung cancer risk and HRT [@pone.0071236-Chlebowski1], [@pone.0071236-Chlebowski2], but Chen et al., Clague et al. and Ramnath et al. showed in their studies that HRT use in females can decrease the incidence of lung cancer [@pone.0071236-Chen1]--[@pone.0071236-Ramnath1].

In order to confirm a definite correlation between HRT and lung cancer risk, we conducted a literature search and performed meta-analysis of available studies.

Materials and Methods {#s2}
=====================

Literature search and identification of the publications {#s2a}
--------------------------------------------------------

A literature search of the PubMed, EMBASE databases and Cochrane Library (updated to May, 2012) was conducted using combinations of the following terms: "hormone replacement therapy", "HRT", "oestrogen replacement therapy", "estrogen replacement therapy", "progestin replacement therapy", "ERT", "lung cancer". We limited the search to studies in human and written in English. Two of the authors (Yanwen Yao and Xiaoling Gu) independently selected the articles with information on the association between HRT and lung cancer morbidity, and further check the reference list of the publications. All studies providing estimates of odd ratio (OR) or relative risk (RR) or hazard ratio (HR) and the corresponding 95% confidence interval (CI), or information sufficient to calculate them, were included in the meta-analysis. Abstracts, reviews, case reports and articles which did not show efficient information were excluded. If multiple studies were published on the same population or subpopulation, the most recent or informative one would be included in the meta-analysis. The flow chart of the selection of publications included in the meta-analysis is shown in [Figure 1](#pone-0071236-g001){ref-type="fig"}. The quality assessment of included studies was further conducted according to the Cochrane handbook 5.1.0 for random control trial (RCT) (<http://www.cochrane.org/training/cochrane-handbook>) and Newcastle-Ottawa Scale (NOS) for non-randomized study such as cohort study and case-control study (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>).

![Flowchart of study identifying and including studies.](pone.0071236.g001){#pone-0071236-g001}

Data extraction {#s2b}
---------------

Information was extracted from all eligible publications independently by two of the authors (Yanwen Yao and Xiaoling Gu). The items included in the data form were as follows: study name (together with the first author\'s name and year of publication), country, study type, study population, age of the subjects, type of used hormone, study-specific ORs or RRs with 95% CI, detailed numbers of patients for "non-HRT user versus HRT user" including "the short period use versus the long period use" and matched or adjusted variables in the analysis. For studies from different countries, the ethnicity of subjects was also collected. Most of the estimated associations between HRT use and lung cancer were adjusted for some factors or their combination. According to the suggestion from Chen et al [@pone.0071236-Chene1], if both the univariate OR/RR and multivariate-adjusted OR/RR were provided, multivariate-adjusted OR/RR was extracted. The lists from the authors were compared, and disagreements were resolved by consensus.

Statistical analyses {#s2c}
--------------------

OR/RR and corresponding 95%CI or detailed numbers of patients in each included study was pooled to evaluate the association between HRT and lung cancer risk. Whenever available, we used multivariate-adjusted risk estimates; otherwise, we utilized or computed distribution given in the papers the unadjusted ORs. Since not all including studies providing ORs/RRs but all the detailed numbers of patients were available, we entered the number of patients with HRT use, non-HRT use, lung cancer patients in HRT users and lung cancer patients in non-HRT users to total meta-analysis. Stratified analyses were also carried out by study type, BMI status, histology, smoking status, and menopause type.

Heterogeneity assumption was evaluated with a chi-square-based Q-test. The summary OR estimate of each study was calculated by a fixed effects model (the Mantel-Haenszel method). If the *P* value is greater than 0.05 of the Q-test, which indicates low heterogeneity or lack of heterogeneity among the included studies, the fixed effects model is proper, otherwise, the random-effects model (the DerSimoniane and Laird method) was performed [@pone.0071236-Mantel1], [@pone.0071236-DerSimonian1]. Sensitive analysis was also performed to evaluate the influence of individual studies on the final effect. Potential publication bias would be observed by the funnel plot and formally evaluated with Begg\'s adjusted rank correlation test and Egger\'s linear regression test. All statistical analysis were done with the Stata software (version 11.0; StataCorp LP, College Station, TX, USA), using two-sided *P* values.

Results {#s3}
=======

Study selection and characteristic in the meta-analysis {#s3a}
-------------------------------------------------------

A total of 25 eligible studies met the inclusion criteria and entered into the final meta-analysis [@pone.0071236-Adami1]--[@pone.0071236-Ramnath1], [@pone.0071236-Blackman1]--[@pone.0071236-Meinhold1]. All studies passed the quality assessment and the result was shown in [Table 1](#pone-0071236-t001){ref-type="table"}. The published years of studies, study types, regions, ethnicity of included patients, the number of patients, the mean age or age range of patients, and type of HRT were all collected. The characteristics of selected studies are presented in [Table 2](#pone-0071236-t002){ref-type="table"}. The time range of studies was from 1988 to 2012. The total number of participates was 656,403 and final 11,442 participates were histologically diagnosed to be lung cancer patients. Four studies were random control trials (RCTs) and ten were case-control studies. Among the total 25 studies, two studies were conducted in the Asian females [@pone.0071236-Chen1], [@pone.0071236-Liu1], five studies were in Caucasian [@pone.0071236-Kreuzer1], [@pone.0071236-Olsson1]--[@pone.0071236-Pukkala1], [@pone.0071236-Slatore1] and the ethnicity in the left studies were mixed or not given. Females in studies of Blackman et al., Kabat et al., Liu et al., Olsson et al. and Smith et al. included young females, who were less than 50 years old [@pone.0071236-Blackman1], [@pone.0071236-Kabat1], [@pone.0071236-Liu1], [@pone.0071236-Olsson1], [@pone.0071236-Smith1]. Estrogen was used alone as HRT in seven studies [@pone.0071236-Adami1], [@pone.0071236-Chlebowski1], [@pone.0071236-Elliott1], [@pone.0071236-Olsson1], [@pone.0071236-Taioli1], [@pone.0071236-Brinton1], [@pone.0071236-Meinhold1], estrogen plus progestin were used as HRT in three studies [@pone.0071236-Chlebowski2], [@pone.0071236-Hulley1], [@pone.0071236-Rossouw1] and estrogen or estrogen plus progestin or the combination of both was used in the left 15 studies. The status of oral contraceptive use in patients was also investigated in nine studies [@pone.0071236-Ramnath1], [@pone.0071236-Elliott1], [@pone.0071236-Kabat1], [@pone.0071236-Kreuzer1], [@pone.0071236-Rodriguez1], [@pone.0071236-Smith1]--[@pone.0071236-Wu1], [@pone.0071236-Meinhold1].

10.1371/journal.pone.0071236.t001

###### Quality assessment scores of the cohort and case-control studies.

![](pone.0071236.t001){#pone-0071236-t001-1}

  Study                                  Study type   Selection   Comparability   Outcome
  ------------------------------------- ------------ ----------- --------------- ---------
  Adami[@pone.0071236-Adami1]              Cohort         4             2            3
  Brinton[@pone.0071236-Brinton1]          Cohort         4             2            3
  Clague[@pone.0071236-Clague1]            Cohort         2             1            3
  Kabat[@pone.0071236-Kabat1]              Cohort         4             2            3
  Liu[@pone.0071236-Liu1]                  Cohort         3             2            3
  Olsson[@pone.0071236-Olsson1]            Cohort         3             2            3
  Persson[@pone.0071236-Persson1]          Cohort         4             2            3
  Pukkala[@pone.0071236-Pukkala1]          Cohort         4             2            3
  Rodriguez[@pone.0071236-Rodriguez1]      Cohort         3             2            3
  Slatore[@pone.0071236-Slatore1]          Cohort         4             2            3
  Smith[@pone.0071236-Smith1]              Cohort         4             2            3

  Study                                 Study type    Selection   Comparability   Exposure
  ----------------------------------- -------------- ----------- --------------- ----------
  Blackman[@pone.0071236-Blackman1]    Case-control       4             1            2
  Chen[@pone.0071236-Chen1]            Case-control       4             2            3
  Elliott[@pone.0071236-Elliott1]      Case-control       4             2            3
  Kreuzer[@pone.0071236-Kreuzer1]      Case-control       4             2            3
  Mahabir[@pone.0071236-Mahabir1]      Case-control       4             2            2
  Meinhold[@pone.0071236-Meinhold1]    Case-control       4             2            3
  Ramnath[@pone.0071236-Ramnath1]      Case-control       3             2            3
  Schabath[@pone.0071236-Schabath1]    Case-control       4             2            3
  Taioli[@pone.0071236-Taioli1]        Case-control       3             2            3
  Wu[@pone.0071236-Wu1]                Case-control       4             2            3

  RCT                                  Chlebowski[@pone.0071236-Chlebowski2]   Chlebowski[@pone.0071236-Chlebowski1]   Hulley[@pone.0071236-Hulley1]   RossouwJE[@pone.0071236-Rossouw1]
  ----------------------------------- --------------------------------------- --------------------------------------- ------------------------------- -----------------------------------
  Adequate sequence generation                           Y                                       Y                                   Y                                 Y
  Allocation concealment                                 Y                                       Y                                   Y                                 Y
  Blinding                                               Y                                       Y                                   Y                                 Y
  Incomplete outcome data addressed                     NA                                       Y                                   Y                                 Y
  Free of seletive reporting                             Y                                       Y                                   Y                                 Y
  Free of other bias                                     Y                                       Y                                   Y                                 Y

10.1371/journal.pone.0071236.t002

###### Baseline information of the 25 included studies in meta-analysis.

![](pone.0071236.t002){#pone-0071236-t002-2}

  Study                                    Year    Region    Ethnicity    Study type    Participants   Cases   Age(years)   Hormone Type        
  --------------------------------------- ------ ---------- ----------- -------------- -------------- ------- ------------ -------------- ----- -----
  Adami[@pone.0071236-Adami1]              1989      US         NG          Cohort         23244        82        54.5                      E   
  Blackman[@pone.0071236-Blackman1]        2002      US        Mixed     Case-control       4188        659      40--74                     E    E+P
  Brinton[@pone.0071236-Brinton1]          2012      US        Mixed        Cohort         118008      2541       64.6                      E    E+P
  Chen[@pone.0071236-Chen1]                2007    China       Asian     Case-control       1357        826        57                       E    E+P
  Chlebowski[@pone.0071236-Chlebowski2]    2009      US        Mixed         RCT           16608        194      50--79                          E+P
  Chlebowski[@pone.0071236-Chlebowski1]    2010      US        Mixed         RCT           10739        115      50--79                     E   
  Clague[@pone.0071236-Clague1]            2011      US        Mixed        Cohort         60592        727      50--77                     E    E+P
  Elliott[@pone.0071236-Elliott1]          2006   Scotland      NG       Case-control       648         162        NG            O          E   
  Hulley[@pone.0071236-Hulley1]            2010      US        Mixed         RCT            2763        64         69                            E+P
  Kabat[@pone.0071236-Kabat1]              2007    Canada       NG          Cohort         89812        750      40--59          O         All  
  Kreuzer[@pone.0071236-Kreuzer1]          2003   Germany    Caucasian   Case-control       1723        800       \<76           O         All  
  Liu[@pone.0071236-Liu1]                  2005    Japan       Asian        Cohort         44677        137      40--69                    All  
  Mahabir[@pone.0071236-Mahabir1]          2008      US        Mixed     Case-control       1601        763        60                      All  
  Meinhold[@pone.0071236-Meinhold1]        2011      US         NG       Case-control       1041        430        66            O          E    E+P
  Olsson[@pone.0071236-Olsson1]            2003    Sweden    Caucasian      Cohort         29508        55       25--65                    All  
  Persson[@pone.0071236-Persson1]          1996    Sweden    Caucasian      Cohort         22597        223       54.5                      E   
  Pukkala[@pone.0071236-Pukkala1]          2001   Finland    Caucasian      Cohort         94505        120        NG                      All  
  Ramnath[@pone.0071236-Ramnath1]          2007      US        Mixed     Case-control       1790        595        61            O         All  
  Rodriguez[@pone.0071236-Rodriguez1]      2008      US         NG          Cohort         72772        659        NG            O         All  
  RossouwJE[@pone.0071236-Rossouw1]        2002      US        Mixed         RCT           16608        104        63                            E+P
  Schabath[@pone.0071236-Schabath1]        2004      US        Mixed     Case-control       1018        499        NG                      All  
  Slatore[@pone.0071236-Slatore1]          2010      US      Caucasian      Cohort         36588        334      50--76                     E    E+P
  Smith[@pone.0071236-Smith1]              2009      US         NG          Cohort          2861        87       31--79          O         All  
  Taioli[@pone.0071236-Taioli1]            1994      US         NG       Case-control       483         180        NG            O          E   
  Wu[@pone.0071236-Wu1]                    1988      US         NG       Case-control       672         336        59            O          E    E+P

RCT: random clinical trial, O: oral contraceptive use, E: estrogen replacement, P: progestin replacement, E+P: estrogen and progestin combination therapy, NG: Not Given or No limitation.

Meta analyses on HRT use and lung cancer risk {#s3b}
---------------------------------------------

ORs and 95% CI were not all demonstrated in the included 25 studies. However, the number of lung cancer patients in HRT users and in non-HRT users were provided in all the studies, so the detailed numbers in the two groups were collected and shown in [Table 3](#pone-0071236-t003){ref-type="table"}. In subgroup analyses, ORs and the corresponding 95% CIs were collected and meta-analyses were performed in different subgroups.

10.1371/journal.pone.0071236.t003

###### Numbers of lung cancer patients in HRT and non-HRT groups from25 studies.

![](pone.0071236.t003){#pone-0071236-t003-3}

                                           HRT user   Non-HRT user                         
  --------------------------------------- ---------- -------------- ------ ------- ------- --------------
  Adami[@pone.0071236-Adami1]                 46         23244        36    23244   1.278   0.826--1.978
  Blackman[@pone.0071236-Blackman1]          145          762        514    2767    1.030   0.839--1.264
  Brinton[@pone.0071236-Brinton1]            1002        67137       1539   45443   0.880   0.812--0.953
  Chen[@pone.0071236-Chen1]                  145          279        681    1078    0.631   0.484--0.823
  Chlebowski[@pone.0071236-Chlebowski2]      109          8506        85    8102    1.224   0.920--1.628
  Chlebowski[@pone.0071236-Chlebowski1]       61          5310        54    5429    1.157   0.800--1.672
  Clague[@pone.0071236-Clague1]              511         45187       216    15405   0.804   0.685--0.944
  Elliott[@pone.0071236-Elliott1]             19           74        143     574    1.041   0.598--1.813
  Hulley[@pone.0071236-Hulley1]               37          1380        27    1383    1.384   0.838--2.285
  Kabat[@pone.0071236-Kabat1]                274         42156       476    47656   0.648   0.559--0.753
  Kreuzer[@pone.0071236-Kreuzer1]            196          470        604    1236    0.748   0.604--0.928
  Liu[@pone.0071236-Liu1]                     24          5276       113    36077   1.454   0.935--2.262
  Mahabir[@pone.0071236-Mahabir1]            298          692        465     909    0.722   0.592--0.881
  Meinhold[@pone.0071236-Meinhold1]          194          505        236     536    0.793   0.619--1.016
  Olsson[@pone.0071236-Olsson1]               8           3040        47    25515   1.430   0.675--3.028
  Persson[@pone.0071236-Persson1]            112         22597       111    22597   1.009   0.776--1.313
  Pukkala[@pone.0071236-Pukkala1]             55         94505        65    94505   0.846   0.591--1.212
  Ramnath[@pone.0071236-Ramnath1]            132          470        463    1320    0.723   0.574--0.910
  Rodriguez[@pone.0071236-Rodriguez1]        355         40013       304    32759   0.956   0.819--1.115
  RossouwJE[@pone.0071236-Rossouw1]           54          8506        50    8102    1.029   0.699--1.513
  Schabath[@pone.0071236-Schabath1]          232          505        267     513    0.783   0.612--1.002
  Slatore[@pone.0071236-Slatore1]            230         23119       104    11642   1.115   0.883--1.407
  Smith[@pone.0071236-Smith1]                 33          1024        54    1837    1.100   0.708--1.707
  Taioli[@pone.0071236-Taioli1]               62          138        118     345    1.569   1.049--2.347
  Wu[@pone.0071236-Wu1]                      149          336        187     336    0.635   0.468--0.861

Test of heterogeneity {#s3c}
---------------------

Heterogeneity between studies was observed regarding both overall comparisons and subgroup analyses. According to the I^2^ and *P* for heterogeneity test listed in the [Table 4](#pone-0071236-t004){ref-type="table"}, the random effect model which based on the Mantel-Haenszel method was adopted when I^2^ ≥50% and *P* for heterogeneity test ≤0.05. Otherwise, the fixed effect model was adopted.

10.1371/journal.pone.0071236.t004

###### Stratified analyses of Hormone therapy on lung cancer risk.

![](pone.0071236.t004){#pone-0071236-t004-4}

                                                Heterogeneity                             
  ------------------------------ ---- -------- --------------- ------- ------------------ -------
  All Studies                     25   Random       68\.        0.000   0.90(0.82--0.98)   0.033
  Case-control studies            10   Random       63.9        0.003   0.81(0.70--0.93)   0.002
  Cohort Studies                  11   Random       70.4        0.000   0.94(0.83--1.06)   0.318
  Random Control studies          4    Fixed         0.0        0.814   1.18(0.99--1.42)   0.073
  BMI\<25 kg/m^2^                 4    Fixed        30.0        0.407   0.65(0.53--0.79)   0.000
  25≤BMI\<30 kg/m^2^              4    Fixed        25.5        0.258   0.84(0.65--1.09)   0.188
  BMI≥30 kg/m^2^                  4    Fixed         0.0        0.434   0.89(0.63--1.26)   0.514
  NSCLC                           6    Random       58.1        0.036   0.93(0.76--1.14)   0.506
  SCLC                            6    Fixed         0.0        0.663   1.05(0.83--1.33)   0.698
  Adenocarcinoma                  9    Random       50.6        0.040   0.96(0.82--1.11)   0.573
  Never Smokers                   11   Fixed         0.0        0.502   0.86(0.75--0.99)   0.042
  Smokers                         10   Random       52.8        0.025   0.94(0.82--1.07)   0.333
  Oral Contraceptive              7    Random       54.2        0.041   0.97(0.80--1.18)   0.772
  Age at Menopause\>52            4    Random       62.0        0.048   0.84(0.60--1.17)   0.297
  Artificial Menopause            4    Fixed         0.0        0.419   1.51(1.17--1.94)   0.001
  Duration of HRT use≤5 years     5    Fixed         0.0        0.553   0.98(0.87--1.10)   0.709
  Duration of HRT use\>5 years    5    Fixed        20.5        0.284   0.99(0.87--1.14)   0.919

As shown in [Table 4](#pone-0071236-t004){ref-type="table"}, *P* for heterogeneity test of lung cancer patients in HRT users vs. non-HRT users for all studies was 0.000 and I^2^ was 67.6%, which meant there was heterogeneity for the meta-analysis, so the random effect model was adopted. In the subgroup analyses, meta-analyses on RCTs, BMI\<25 kg/m^2^, 25≤BMI\<30 kg/m^2^, BMI≥30 kg/m^2^, small cell lung cancer (SCLC), never smokers, artificial menopause, duration of HRT use≤5 years and duration of HRT use\>5 years were performed on the fixed effect model, other subgroup analyses were used random effect models.

Meta-analysis results {#s3d}
---------------------

The result of the meta-analysis on the all 25 studies and the forest plot was shown in [Table 3](#pone-0071236-t003){ref-type="table"} and [Figure 2](#pone-0071236-g002){ref-type="fig"}. OR was 0.91(95%CI  = 0.83 to 0.99) and *P* value of the test for overall effect was 0.033 when analysis performed using random effect model. This result suggested that HRT use was associated with a significant decrease risk of lung cancer compared with non-HRT use in females. A cumulative meta-analysis was further conducted to confirm the result. As shown in [Figure 3](#pone-0071236-g003){ref-type="fig"}, the result was shifted to an association between HRT use and a significant decrease risk of lung cancer when the evidence was tracked over time.

![Meta-analysis with a random-effects model for the association between HRT use and cancer risk in females. CI: confidence interval.](pone.0071236.g002){#pone-0071236-g002}

![A cumulative meta-analysis tracked over time with a random-effects model for the association between HRT use and cancer risk in females.\
CI: confidence interval.](pone.0071236.g003){#pone-0071236-g003}

Since heterogeneity was revealed in the overall meta-analysis, subgroup analyses were performed after stratifications of data by study type, BMI status, histology, smoking status, oral contraceptive use, menopause type, and duration of HRT use. The overall ORs and corresponding 95% CI of subgroup analyses were demonstrated in [Table 4](#pone-0071236-t004){ref-type="table"}. In analysis of ten case-control studies, the association between significant decreased lung cancer risk and HRT use was also been revealed, while increased lung cancer risk was correlated with HRT use according to the meta-analysis of four RCTs but the difference is not significant. The forest plot of the study type subgroup analysis is demonstrated in [Figure 4](#pone-0071236-g004){ref-type="fig"}--A. In the analysis of different types of hormone replacement therapy, estrogen, progestin or the combination of both were used in participates in 17 studies. The sub-analysis result of these 17 studies revealed that this type of hormone use could reduce the lung cancer risk (OR = 0.83, 95%CI 0.76--0.91, P = 0.000) ([Figure 4](#pone-0071236-g004){ref-type="fig"}--B). Five studies in which estrogen was used as the replacement hormone demonstrated that although the difference was not significant, only estrogen use could increase the lung cancer risk (OR = 1.16, 95%CI 0.98--1.37, P = 0.079).

![A: Meta-analysis with a random-effects model for the association between HRT use and cancer risk in females stratified by study type.\
B: Meta-analysis with a random-effects model for the association between HRT use and cancer risk in females stratified by hormone type. CI: confidence interval.](pone.0071236.g004){#pone-0071236-g004}

As shown in [Table 4](#pone-0071236-t004){ref-type="table"} and [Figure 5](#pone-0071236-g005){ref-type="fig"}, the positive association between HRT use and decreased lung cancer risk was found in the patients with never smokers patients (OR = 0.86, 95%CI 0.75--0.99, *P* = 0.042), and BMI\<25 kg/m^2^ (OR = 0.65, 95%CI 0.53--0.79, *P* = 0.000). However, HRT use in patients with artificial menopause increased the lung cancer risk (OR = 1.51, 95%CI 1.17--1.94, *P* = 0.001). A subgroup analysis was also done on HRT use in smokers, but the evidence showed negative correlation between smoking and the risk of lung cancer, *P* = 0.333.

![Meta-analysis for the significant association between cancer risk and HRT use in females with artificial menopause or BMI\<25 kg/m^2^ or non-smoking females.\
CI: confidence interval.](pone.0071236.g005){#pone-0071236-g005}

Publication bias {#s3e}
----------------

The publication bias of the literatures was assessed by using Begg\'s funnel plot and Egger\'s test. The shape of the funnel plots seemed approximately symmetrical ([Figure 6](#pone-0071236-g006){ref-type="fig"}) and the result of Egger\'s test did not show any evidence of publican bias, t = 1.91 and *P* = 0.069 for HRT use vs. non-HRT use.

![Begg\'s funnel plot of publication bias test.\
Each point represents a separate study for the indicated association. Log (OR): natural logarithm of OR; Horizontal line: mean effect size.](pone.0071236.g006){#pone-0071236-g006}

Sensitivity analysis {#s3f}
--------------------

Sensitivity analysis was also analyzed as previous study ([Table 5](#pone-0071236-t005){ref-type="table"} and [Figure 7](#pone-0071236-g007){ref-type="fig"}) [@pone.0071236-Zhang1]. As shown in [Figure 7](#pone-0071236-g007){ref-type="fig"}, none of the studies appears to be an outlier or has results very different from the rest of the studies. After each study was excluded from the overall meta-analysis, the similar results were obtained, which suggested that the result of the meta-analysis was stable.

![Sensitivity analysis of the included 25 studies.\
Each point represents a OR and corresponding 95%CIs after excluding each study.](pone.0071236.g007){#pone-0071236-g007}

10.1371/journal.pone.0071236.t005

###### Sensitivity analysis: ORs, corresponding 95%CIs and *P* values after excluding each study.
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  Excluded Study                            OR        95%CI       *P* value
  --------------------------------------- ------- -------------- -----------
  Adami[@pone.0071236-Adami1]              0.899   0.823--0.983     0.019
  Blackman[@pone.0071236-Blackman1]        0.902   0.823--0.989     0.028
  Brinton[@pone.0071236-Brinton1]          0.917   0.829--1.015     0.095
  Chen[@pone.0071236-Chen1]                0.922   0.843--1.007     0.072
  Chlebowski[@pone.0071236-Chlebowski2]    0.895   0.819--0.978     0.014
  Chlebowski[@pone.0071236-Chlebowski1]    0.901   0.823--0.985     0.022
  Clague[@pone.0071236-Clague1]            0.917   0.835--1.007     0.071
  Elliott[@pone.0071236-Elliott1]          0.906   0.828--0.991     0.032
  Hulley[@pone.0071236-Hulley1]            0.899   0.823--0.982     0.018
  Kabat[@pone.0071236-Kabat1]              0.923   0.847--1.005     0.064
  Kreuzer[@pone.0071236-Kreuzer1]          0.918   0.837--1.007     0.069
  Liu[@pone.0071236-Liu1]                  0.895   0.820--0.977     0.013
  Mahabir[@pone.0071236-Mahabir1]          0.920   0.839--1.008     0.073
  Meinhold[@pone.0071236-Meinhold1]        0.915   0.834--1.003     0.059
  Olsson[@pone.0071236-Olsson1]            0.903   0.826--0.987     0.024
  Persson[@pone.0071236-Persson1]          0.904   0.825--0.991     0.031
  Pukkala[@pone.0071236-Pukkala1]          0.911   0.832--0.998     0.045
  Ramnath[@pone.0071236-Ramnath1]          0.919   0.839--1.007     0.069
  Rodriguez[@pone.0071236-Rodriguez1]      0.907   0.826--0.997     0.042
  RossouwJE[@pone.0071236-Rossouw1]        0.905   0.827--0.991     0.031
  Schabath[@pone.0071236-Schabath1]        0.916   0.835--1.004     0.061
  Slatore[@pone.0071236-Slatore1]          0.898   0.821--0.983     0.019
  Smith[@pone.0071236-Smith1]              0.904   0.826--0.989     0.028
  Taioli[@pone.0071236-Taioli1]            0.891   0.817--0.971     0.008
  Wu[@pone.0071236-Wu1]                    0.920   0.842--1.006     0.068

Discussion {#s4}
==========

To date, the current and estimated morbidity and mortality of lung cancer in females are still less than that in males [@pone.0071236-Siegel2]. Although much has been learned about the epidemiology, the reason is still unclear. Besides the different smoking status, the kind and altering levels of endogenous and exogenous hormone in males and females has become to be the subject of the epidemiology study.

As the most common therapy for menopausal females and young females with artificial menopause, HRT has been proved to be associated with increased risk of breast cancer and endometrial cancer and decreased risk of colorectal cancer and coronary heart disease [@pone.0071236-Gompel1]--[@pone.0071236-Low1]. The role of HRT in lung cancer incidence has also been investigated in several studies. Wu et al in their study firstly demonstrated that the menopause type and hormone intake were associated with the lung cancer risk in female [@pone.0071236-Wu1]. Previous studies in past years revealed the controversial association between HRT and lung cancer risk.

Our meta-analysis of total 25 studies on HRT use and lung cancer risk demonstrated that HRT use in female could decrease the risk of lung cancer. The positive correlation was also identified between decreased lung cancer risk and HRT use in females with BMI\<25 kg/m^2^ and never smokers, increased lung cancer risk and HRT users with artificial menopause.

Estrogen in HRT was considered to be the most likely candidate for mediating growth-promoting effect in lung cancer, because evidence showed that expression of estrogen receptors (ER) in lung cancer mediated transcriptional responses in lung cancer cells [@pone.0071236-Ganti1]--[@pone.0071236-Siegfried1]. On the other side, progestin which is also a type of hormone in HRT is reported to take a protect role against lung cancer [@pone.0071236-Siegfried1], [@pone.0071236-Ishibashi1]. In the study of Ishibashi, progestin receptor was revealed to be in about half of lung cancer, and progestin mediated pathways to induce apoptosis and reduce growth in lung cancer cells [@pone.0071236-Ishibashi1]. These results demonstrated that HRT can act tumor growth-promoting or tumor growth-suppressing effects depending on the components of HRT, the expressions of estrogen receptors and progestin receptors.

Moore et al firstly suggested in his study that according to the respective data, young women (age from 31 to 50 years) presented more often with advanced disease [@pone.0071236-Moore1]. This may help to explain why HRT users with artificial menopause who were always young women had increased lung cancer risk. The mechanism involved may be estrogen plays a deleterious role in lung cancer in younger female patients, especially in early stage disease [@pone.0071236-Moore1]. The reason for undefined risk in smoking HRT users may be that higher circulating levels of estrogen in women make susceptible to the carcinogenic influence of tobacco smoke [@pone.0071236-Thomas1].

The analyses showed that the ORs and significance were different in case control studies, cohort studies and RCT. As provided in each article, all females in four RCT studies included in this meta-analysis, were postmenopausal women, with the age range or the mean age of 50--79, 50--79, 69 and 63, respectively. While in cohort and case-control studies, females were younger than those in RCTs, suggesting these females were not in the menopause or were close to the menopause.

Vandenbroucke JP [@pone.0071236-Vandenbroucke1] indicated that adjustment for previous use of hormones already increased the estimates in the trials. HRT is usually started close to menopause, so the observational studies had shown a relatively true situation. However, this situation was diluted in the randomized trial because fewer women close to menopause were enrolled. The discrepancy between the RCT and observational study was not only in HRT and lung cancer, but also in HRT and coronary heart disease, and breast cancer. It was not due to differences in study design, but to the timing of start of treatment.

Randomized trials are necessary for showing whether the benefit of a medical intervention exists [@pone.0071236-Prentice1]. In contrast, observational study is often used to investigate adverse effects [@pone.0071236-Vandenbroucke2]. It was suggested that the same adverse effect for the same treatment can rarely be investigated by observational research and in very large randomized trials [@pone.0071236-Vandenbroucke3], such as breast cancer and HRT, and lung cancer and HRT shown in our meta-analysis. Vandenbroucke JP also suggested that observational studies may better reflect the true harm in real-life than selected populations in randomized trials [@pone.0071236-Vandenbroucke1].

In the subgroup analyses HRT use was confirmed to be associated with decreased lung cancer risk in non-smoking females. However, HRT use in ever smoking females failed to be associated with lung cancer risk. The fact that smoking can induced increased lung cancer risk in females could help to explain the result. In a study on smoking-related mortality in the United States, smoking was shown to be also hazardous for women comparable to men [@pone.0071236-Thun1]. Since smoking and other socio-economic status were proved to be associated with increased lung cancer risk, the effect of HRT may be potentially confounding by these factors.

The present study provides a quantitative analysis of available epidemiologic studies on HRT and lung cancer risk in females. There is a broad time span in the 25 studies, from 1988 to 2012, and the sample size is large (total 656,403 participates). Stratified analyses were conducted. Heterogeneity was tested and random-effects model was used to estimate the magnitude of the heterogeneity and assign a greater variability to the combined risk estimate to account for the heterogeneity if detected. Publication bias was also examined and corrected if detected.

Some limitations of this meta-analysis should be acknowledged. First, many observational studies which were susceptible to various biases were included in our meta-analyses. The subgroup analysis in different types of studies showed different results. However, taking these results together still shows the positive association between HRT and lung cancer risk. Second, although subgroup analyses was proceed by the kind of HRT, HRT dose which may also affects the result were not taking into analysis. Finally, only published studies were included in our meta-analysis. Therefore, publication bias may be occurred although no publication bias was indicated from both funnel plot and Egger\'s test.

Conclusion {#s4a}
----------

Taken together, our analysis of currently available studies on HRT and lung cancer risk suggests that HRT use is correlated with decreased lung cancer risk in female, especially in female with BMI\<25 kg/m^2^ and never smokers, but HRT in female with artificial menopause could increase the lung cancer risk. Considering that lung cancer is one of the leading causes of death in female, further investigations or larger observational study with women closer to menopause rather than postmenopausal was needed in future to further validate the influence of HRT in lung cancer.
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